Law firm questions fairness of Nuvalent's $124/share sale to GSK amid higher analyst price targets.

Wohl & Fruchter LLP is investigating whether the proposed sale of Nuvalent, Inc. to GSK for $124 per share is fair to shareholders, noting this price is below several Wall Street analysts' targets, which range from $126 to $158 per share. The firm is examining if Nuvalent's board acted in shareholders' best interests and fully disclosed all material information and conflicts related to the deal. Shareholders concerned about the sale price are encouraged to contact the law firm for a free consultation. This investigation highlights potential shareholder dissatisfaction with the sale terms and could impact the transaction's progress.